Loading…

Daily, intermittent intravenous infusion of peptide YY(3-36) reduces daily food intake and adiposity in rats

1 Department of Veterans Affairs, Nebraska Western Iowa Health Care System, Omaha; 2 Biomedical Sciences Department, Creighton University, Omaha, Nebraska; 3 Center for Ulcer Research and Education: Digestive Diseases Research Center, Department of Veterans Affairs, Greater Los Angeles Healthcare Sy...

Full description

Saved in:
Bibliographic Details
Published in:American journal of physiology. Regulatory, integrative and comparative physiology integrative and comparative physiology, 2006-02, Vol.290 (2), p.R298-R305
Main Authors: Chelikani, Prasanth K, Haver, Alvin C, Reeve, Joseph R., Jr, Keire, David A, Reidelberger, Roger D
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:1 Department of Veterans Affairs, Nebraska Western Iowa Health Care System, Omaha; 2 Biomedical Sciences Department, Creighton University, Omaha, Nebraska; 3 Center for Ulcer Research and Education: Digestive Diseases Research Center, Department of Veterans Affairs, Greater Los Angeles Healthcare System, Los Angeles; and 4 Digestive Diseases Division, David Geffen University of California at Los Angeles School of Medicine, Los Angeles, California Submitted 15 September 2005 ; accepted in final form 3 October 2005 The gut hormone peptide YY(3-36) [PYY(3-36)] decreases food intake when administered by intravenous infusion to lean and obese humans and rats. Whether chronic administration of PYY(3-36) produces a sustained reduction in food intake and adiposity is the subject of intense debate. Batterham et al. (R. L. Batterham, M. A. Cowley, C. J. Small, H. Herzog, M. A. Cohen, C. L. Dakin, A. M. Wren, A. E. Brynes, M. J. Low, M. A. Ghatei, R. D. Cone, and S. R. Bloom. Nature 418: 650–654, 2002) first reported that PYY(3-36) reduces food intake and weight gain in rats when injected into the peritoneal cavity twice daily for 7 days. Numerous laboratories have failed to confirm that daily injections of PYY(3-36) decrease body weight. Continuous subcutaneous administration of PYY(3-36) by osmotic minipump has been reported to reduce daily food intake in rodents but only during the first 3–4 days of administration. Here we show the effects of different daily patterns of intravenous infusion of PYY(3-36) on food intake, body weight, and adiposity in rats tethered via infusion swivels to computer-controlled pumps. Measurement of food bowl weight recorded by computer every 20 s permitted daily assessment of the instantaneous effects of PYY(3-36) administration on food intake and meal patterns. One-hour intravenous infusions of PYY(3-36) at 30 pmol·kg –1 ·min –1 every other hour for 10 days produced a sustained reduction in daily food intake of 20% and decreased body weight and adiposity by 7 and 35%, respectively. Thus dosage pattern is critical for producing a sustained effect of PYY(3-36) on food intake and adiposity. gastrointestinal; body weight; body composition Address for reprint requests and other correspondence: R. D. Reidelberger, Veterans Affairs, Nebraska Western Iowa Health Care System (151), 4101 Woolworth Ave., Omaha, NE 68105 (e-mail: roger.reidelberger{at}med.va.gov )
ISSN:0363-6119
1522-1490
DOI:10.1152/ajpregu.00674.2005